4D Molecular Therapeutics FDMT Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Prepaid Expense and Other Assets at other companies
Other financials
Where this comes from
Reported directly by 4D Molecular Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: 4D Molecular Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about 4D Molecular Therapeutics's increase (decrease) in prepaid expense and other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is 4D Molecular Therapeutics's increase (decrease) in prepaid expense and other assets?
- 4D Molecular Therapeutics (FDMT) reported increase (decrease) in prepaid expense and other assets of $3.99M in Q1 2026.
- How has 4D Molecular Therapeutics's increase (decrease) in prepaid expense and other assets changed year-over-year?
- 4D Molecular Therapeutics's increase (decrease) in prepaid expense and other assets increased by 271.8% year-over-year, from $1.07M to $3.99M.
- What does increase (decrease) in prepaid expense and other assets mean?
- This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.